{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:03:31Z","timestamp":1792047811313,"version":"4.4.0"},"reference-count":120,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"German Research Foundation - Deutsche Forschungsgemeinschaft","award":["KA 5558\/1-1"],"award-info":[{"award-number":["KA 5558\/1-1"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2026,4,3]]},"DOI":"10.1080\/13543776.2026.2627911","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:03:46Z","timestamp":1770282226000},"page":"333-361","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present)"],"prefix":"10.1080","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2717-5364","authenticated-orcid":false,"given":"Dmitrii V.","family":"Kalinin","sequence":"first","affiliation":[{"name":"University of Galway","place":["Galway, Ireland"]},{"name":"University of M\u00fcnster","place":["M\u00fcnster, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.01.023"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13235"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2017.07.009"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-753202"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112753"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2021.1945580"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-025-00114-x"},{"key":"e_1_3_4_10_1","unstructured":"CSL. European Commission Approves CSL\u2019s ANDEMBRY\u00ae (garadacimab) for the prevention of Recurrent Attacks of hereditary angioedema (HAE). CSL Newsroom. 2025 Feb 13 [cited 2025 Aug 12]. Available from: https:\/\/newsroom.csl.com\/2025-02-13-European-Commission-Approves-CSLs-ANDEMBRY-R-garadacimab-for-the-Prevention-of-Recurrent-Attacks-of-Hereditary-Angioedema-HAE"},{"key":"e_1_3_4_11_1","unstructured":"A Phase IIa randomized open-label proof-of-concept study to evaluate safety tolerability and efficacy of Ir-CPI in patients with spontaneous intracerebral haemorrhage [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05970224"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018016337"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-292094"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2018.08.006"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2305-5839.2015.09.07"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2024.07.001"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1107\/S2059798325005297"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052458"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12195-020-00657-6"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02011"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-569111"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-08-0668"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.238493"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-540872"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006804"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-499111"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17648-w"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12430"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1327.1999.00593.x"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.06.028"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.12968\/hmed.2019.80.7.391"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.20008"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14209"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI77139"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.4.1.13"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01115"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00350-1"},{"key":"e_1_3_4_38_1","unstructured":"CSL Behring. CSL Behring presents results for garadacimab as preventive treatment in hereditary angioedema. 2020 [cited 2021 Jan]. Available from: https:\/\/www.cslbehring.com\/newsroom\/2020\/eaaci-2020-garadacimab-data"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11626"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12217"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.6.2337.bloodjournal8762337"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116201"},{"key":"e_1_3_4_43_1","unstructured":"Davie RL Edwards HJ Evans DM et al. KalVista Pharmaceuticals Ltd. GB. Enzyme inhibitors. WO2021032933. 2021."},{"key":"e_1_3_4_44_1","unstructured":"Davie RL Edwards HJ Evans DM et al. KalVista Pharmaceuticals Ltd. GB. Enzyme inhibitors. WO2021032934. 2021."},{"key":"e_1_3_4_45_1","unstructured":"Childs ML Davie RL Edwards HJ et al. KalVista Pharmaceuticals Ltd. GB. Enzyme inhibitors. WO2021032935. 2021."},{"key":"e_1_3_4_46_1","unstructured":"Edwards HJ Evans DM Mazzacani A et al. KalVista Pharmaceuticals Ltd. GB. Enzyme inhibitors. WO2021032936. 2021."},{"key":"e_1_3_4_47_1","unstructured":"Rao A Mckittrick BA Lombardo M et al. Merck Sharp & Dohme corp. USA. Factor XIIa inhibitors. WO 2018093695. 2018."},{"key":"e_1_3_4_48_1","unstructured":"Hicks J Mckittrick BA Whitehead B et al. Merck Sharp & Dohme corp. USA. Factor XIIa inhibitors. WO2018093716. 2018."},{"key":"e_1_3_4_49_1","unstructured":"Philippou H Foster R Fishwick C et al. University of Leeds. USA. Factor XIIa inhibitors. WO2019211585. 2019."},{"key":"e_1_3_4_50_1","unstructured":"Philippou H Foster R Fishwick C et al. University of Leeds. USA. Factor XIIa inhibitors. WO2019186164. 2019."},{"key":"e_1_3_4_51_1","unstructured":"Childs ML Davie RL Edwards HJ et al. KalVista Pharmaceuticals Ltd. GB. Enzyme inhibitors. WO2022118016. 2022."},{"key":"e_1_3_4_52_1","unstructured":"Davie RL Edwards HJ Fromont C et al. KalVista Pharmaceuticals Ltd. GB. Factor XIIa inhibitors. WO2022175675. 2022."},{"key":"e_1_3_4_53_1","unstructured":"Davie RL Edwards HJ Evans DM et al. KalVista Pharmaceuticals Ltd. GB. 2-Aza- and 2-oxabicyclo[2.1.1]hexane derivatives as factor XIIa enzyme inhibitors. WO2024038282. 2024."},{"key":"e_1_3_4_54_1","unstructured":"Davie RL Evans DM North CL et al. KalVista Pharmaceuticals Ltd. GB. 3a 4 5 6-tetrahydro-1 H-pyrazolo[3 4-c]pyridin-7(7aH)-one derivatives as factor XIIa inhibitors. WO 2024084217. 2024."},{"key":"e_1_3_4_55_1","unstructured":"Cecil ARL Gorsuch S Moore G et al. KalVista Pharmaceuticals Ltd. GB. Solid forms of an enzyme inhibitor and salts thereof. WO2024218503. 2024."},{"key":"e_1_3_4_56_1","unstructured":"Xie Z Meng Z Liao C. Intelligent Manufacturing Institute of Hefei University Technology. China. Compound and stereoisomer thereof or pharmaceutically acceptable salt and application thereof. CN116730980. 2023."},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01635"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00475"},{"key":"e_1_3_4_59_1","unstructured":"Xie Z Chen F Meng Z et al. Intelligent Manufacturing Institute of Hefei University Technology. China. Compound used as blood coagulation factor XIIa inhibitor and pharmaceutical composition and application thereof. CN118239923. 2024."},{"key":"e_1_3_4_60_1","unstructured":"Foster R Abas PS Ayres J et al. Lunac Therapeutics Ltd. GB. Factor XIIa inhibitors. WO2022248883. 2022."},{"key":"e_1_3_4_61_1","unstructured":"Hiroaki S Takayuki K. The University of Tokyo. Japan. Library construction method cyclic peptide FXIIa binder and IFNGR1 binder. WO2021132661. 2021."},{"key":"e_1_3_4_62_1","unstructured":"Hiroaki S Takayuki K. The University of Tokyo. Japan. Library construction method cyclic peptide FXIIa binder and IFNGR1 binder. US20230117920. 2023."},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41557-020-0525-1"},{"key":"e_1_3_4_64_1","unstructured":"Craik DJ De Veer SJ Huang Y-H et al. The University of Queensland. Australia. The University of Tokyo. Japan. Proteinaceous molecules and uses therefor. WO2023060319. 2023."},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi9929756"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389203043379477"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.9b00402"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00557"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.460030"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.1c07574"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.4c00352"},{"key":"e_1_3_4_72_1","unstructured":"Stavrou EX. The United States government as represented by the department of veterans affairs and Case Western reserve University. USA. Factor XII binding peptides and methods of use. WO2025006536. 2025."},{"key":"e_1_3_4_73_1","unstructured":"Lai R Wang W Fang M et al. Kunming Institute of Zoology. China. A cyclic peptide CycloSD6 targeting the contact kinin system and its application. CN119735647. 2025."},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.010909.105654"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/35078107"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw236"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja505986a"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3802"},{"key":"e_1_3_4_79_1","article-title":"Ionis Pharmaceuticals, Inc. USA. Compounds and methods for modulating Factor XII","author":"Freier S","year":"2022","unstructured":"Freier S, Bui H-H, Zhao C, et al. Ionis Pharmaceuticals, Inc. USA. Compounds and methods for modulating Factor XII. WO2022133278. 2022.","journal-title":"WO2022133278"},{"key":"e_1_3_4_80_1","unstructured":"Schmidt K Schlegel M Castoreno A. Alnylam Pharmaceuticals Inc. USA. Factor XII (F12) iRNA compositions and methods of use thereof. WO2023019246. 2023."},{"key":"e_1_3_4_81_1","unstructured":"Li Z Pei T Kanner S et al. Arrowhead Pharmaceuticals Inc. USA. Compositions and methods for inhibition of factor XII gene expression. WO2018140920. 2018."},{"key":"e_1_3_4_82_1","unstructured":"Wang S Huang H Wang Y et al. Beijing Winsunny Pharmaceutical Co Ltd. China. Double-stranded ribonucleic acid used to inhibit expression of FXII gene and modifier conjugate and use thereof. WO2024169577. 2024."},{"key":"e_1_3_4_83_1","unstructured":"Pixley RA Colman RW. Temple University. USA. Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same. WO1989011865. 1989."},{"key":"e_1_3_4_84_1","unstructured":"Esnouf MP. Coagen Ltd GB Blood-coagulation factor XIIa beta monoclonal antibody and immunoassay. WO9008835. 1990."},{"key":"e_1_3_4_85_1","unstructured":"Nuijens JH Huijbregtsc CCM Hack CE et al. Inhibitors of factor XII activation and applications thereof. WO1991017258. 1991."},{"key":"e_1_3_4_86_1","unstructured":"Panousis C Rayzman V Nash A et al. Behring Gmbh. Germany. Inhibitory anti-factor XII\/XIIa monoclonal antibodies and their uses. WO2013014092. 2013."},{"key":"e_1_3_4_87_1","unstructured":"Gruber A Gailani D Leung P et al. Vanderbilt University Aronora Inc. Oregon Health & Science University. USA. Antibodies against factor XII and uses thereof. WO2014089493. 2014."},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.1106.1106"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.2268.2268"},{"key":"e_1_3_4_90_1","unstructured":"Pragst I Pawaskar D Yuraszeck T et al. CSL Innovation Pty Ltd. Australia. Use of an anti-factor XII antibody for the treatment or prevention of hereditary angioedema. WO2021108862. 2021."},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02180-2"},{"key":"e_1_3_4_92_1","article-title":"Inc. USA. Anti-factor XII\/XIIa antibodies and uses thereof","author":"Chalothorn D","year":"2019","unstructured":"Chalothorn D, Morton L, Mitnaul L, et al. Inc. USA. Anti-factor XII\/XIIa antibodies and uses thereof. WO2019246176. 2019.","journal-title":"WO2019246176"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1324022111"},{"key":"e_1_3_4_94_1","unstructured":"Yancopoulos G Chalothorn D Morton L et al. Regeneron Pharmaceuticals Inc. And Yancopoulos G. D. USA. Anti-factor XII\/XIIa antibodies and uses thereof. WO2025019789. 2025."},{"key":"e_1_3_4_95_1","unstructured":"Gruber A Tucker E Wallisch M et al. Oregon Health & Science University and Aronora Inc. USA. Therapeutic factor XII antibody. WO2020113084. 2022."},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1395854"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12309"},{"key":"e_1_3_4_98_1","unstructured":"Zhang C Fu W Cui J et al. Staidson Beijing Biopharmaceuticals Co. China. Antibody specifically recognizing factor XIIa and use thereof. WO2024255794. 2024."},{"key":"e_1_3_4_99_1","unstructured":"Zhang C Liu H Li P. Staidson Beijing Biopharmaceuticals Co. Ltd. China. Antibody capable of specifically recognizing factor XIIa and application thereof. CN119143881. 2024."},{"key":"e_1_3_4_100_1","unstructured":"Wang L Shen C Kong B et al. Beijing Tuojie Biomedical Technology Co. China. FXII\/FXIIa binding proteins and medical uses thereof. CN119119280. 2024."},{"key":"e_1_3_4_101_1","unstructured":"Wang M Xu P. Ningbo Comgen Biotech Co. Ltd. China. Anti-factor XII (FXII) nanobody or antigen-binding fragment thereof and use thereof. WO2021253662. 2024."},{"key":"e_1_3_4_102_1","unstructured":"Wang M Xu P. Ningbo Comgen Biotech Co. Ltd. China. Anti-factor XII (FXII) nanobody or antigen-binding fragment thereof and use thereof. US20240352150. 2024."},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01780-w"},{"key":"e_1_3_4_104_1","unstructured":"Bruder J Liu Y. REGENXBIO Inc. USA. Vectorized factor XII antibodies and administration thereof. WO2022094255. 2022."},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0987-2"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2022.2026926"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2020.1705783"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2024.08.011"},{"key":"e_1_3_4_109_1","unstructured":"A Phase 3 randomized double-blind parallel-group placebo-controlled study to demonstrate the efficacy and safety of Milvexian an oral factor XIa inhibitor for stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05702034"},{"key":"e_1_3_4_110_1","unstructured":"A Phase 3 randomized double-blind double-Dummy parallel group active-controlled study to evaluate the efficacy and safety of Milvexian an oral factor XIa inhibitor versus apixaban in participants with atrial fibrillation [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05757869"},{"key":"e_1_3_4_111_1","unstructured":"A Phase 3 randomized Double-blind placebo-controlled event-driven study to demonstrate the efficacy and safety of Milvexian an oral factor XIa inhibitor after a recent acute coronary syndrome [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05754957"},{"key":"e_1_3_4_112_1","unstructured":"A multicenter International randomized placebo controlled Double-blind parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05686070"},{"key":"e_1_3_4_113_1","unstructured":"A multicenter International randomized active comparator-controlled double-blind double-dummy parallel-group 2-arm Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05643573"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407105"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1717-7958"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.12.038"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.1.170"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2451789"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-024-03958-z"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-023-00615-9"},{"key":"e_1_3_4_121_1","unstructured":"KalVista Pharmaceuticals Inc. KalVista Pharmaceuticals announces FDA approval of EKTERLY (sebetralstat) first and only oral on-demand treatment for hereditary angioedema. Press release. 2025. Jul 7 [cited 2025 Aug 14]. URL https:\/\/ir.kalvista.com\/news-releases\/news-release-details\/kalvista-pharmaceuticals-announces-fda-approval-ekterlyr"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.900"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2627911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:34:58Z","timestamp":1775039698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2026.2627911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":120,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,3]]}},"alternative-id":["10.1080\/13543776.2026.2627911"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2026.2627911","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}